About Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals is a company based in Princeton (United States) founded in 2015 was acquired by Viatris in November 2022. Oyster Point Pharmaceuticals has raised $121.61 million across 2 funding rounds from investors including Viatris, Invus and Flying L Partners. The company has 303 employees as of December 31, 2021. Oyster Point Pharmaceuticals offers products and services including EFFEXOR and Generics. Oyster Point Pharmaceuticals operates in a competitive market with competitors including Remegen, Biophytis, Azura Ophthalmics, TearSolutions and Retrotope, among others.
- Headquarter Princeton, United States
- Employees 303 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oyster Point Pharma, Inc.
-
Annual Revenue
$24.54 M (USD)0as on Dec 31, 2021
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$121.61 M (USD)
in 2 rounds
-
Latest Funding Round
$93 M (USD), Series B
Feb 26, 2019
-
Investors
Viatris
& 5 more
-
Employee Count
303
as on Dec 31, 2021
-
Acquired by
Viatris
(Nov 07, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals offers a comprehensive portfolio of products and services, including EFFEXOR and Generics.
Medication for treating generalized anxiety disorder.
Affordable alternatives to branded drugs for various conditions.
People of Oyster Point Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals has successfully raised a total of $121.61M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $93 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Viatris, Invus and Flying L Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked | |
|
Flying L Partners is focused on ophthalmic sector investments.
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked |
Investor details for Oyster Point Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Oyster Point Pharmaceuticals
Investment portfolio details for Oyster Point Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Oyster Point Pharmaceuticals
Detailed financials for Oyster Point Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oyster Point Pharmaceuticals Comparisons
Peer comparison for Oyster Point Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Remegen, Biophytis, Azura Ophthalmics, TearSolutions and Retrotope, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for cancer, autoimmune, and eye diseases are developed.
|
|
| Locked | Locked | Locked |
Drugs for neuromuscular and age-related diseases are developed.
|
|
| Locked | Locked | Locked |
Developing therapies for meibomian gland dysfunction
|
|
| Locked | Locked | Locked |
Topical therapeutics for the treatment of dry eye disease
|
|
| Locked | Locked | Locked |
Therapeutics for neurodegenerative and ophthalmological diseases are developed.
|
Detailed competitors of Oyster Point Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oyster Point Pharmaceuticals
Complete news archive for Oyster Point Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Oyster Point Pharmaceuticals is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Jeffrey Nau is the current CEO of Oyster Point Pharmaceuticals.
Oyster Point Pharmaceuticals is a funded company, having raised a total of $121.61M across 2 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Oyster Point Pharmaceuticals is 303.
Annual revenue of Oyster Point Pharmaceuticals is $24.54M as on Dec 31, 2021.
Founded in 2015 and headquartered in Princeton, United States, the company focuses on biotechnology within the ophthalmology sector. Gene therapies targeting ocular surface diseases are developed using an adeno-associated virus-based approach known as Enriched Tear Film therapy. The pipeline encompasses OC-01, a nasal spray for dry-eye disease; OC-103, intended for severe allergic conjunctivitis; and OC-101, aimed at neurotrophic keratopathy. Operations center on advancing these therapies through clinical development.
Oyster Point Pharmaceuticals's top competitors include Remegen, Lineage Cell Therapeutics and TearSolutions.
Oyster Point Pharmaceuticals offers EFFEXOR and Generics.
Oyster Point Pharmaceuticals has 6 investors. Key investors include Viatris, Invus, Flying L Partners, NEA, and Versant Ventures.